Top Markets
#1 Siren Siren +33.59%
#2 Wiki Cat Wiki Cat +27.83%
#3 Ribbita by Virtuals Ribbita by Virtuals +17.67%
#4 PulseChain PulseChain +16.92%
#5 Bitway Bitway +16.87%
#6 Velvet Velvet +16.62%
#7 Cysic Cysic +15.53%
#8 TRIA TRIA +15.19%
#9 KUB Coin KUB Coin +14.61%
#10 Nockchain Nockchain +13.92%
Coin of the day
Siren Siren
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rang in Aktien #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Aktienkurs
$0.089
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$15.36M
Veränderung (1 Tag)
50.59%
Veränderung (1 Jahr)
111.85%
Land
US
Handel Inhibitor Therapeutics, Inc. (INTI)

Kategorie

Healthcare
P/B-Verhältnis für Inhibitor Therapeutics, Inc. (INTI)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Inhibitor Therapeutics, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Inhibitor Therapeutics, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE